	US 12,448,465 B2
	Peptides
Peter Ellmark, Lund (SE); Karin Hagerbrand, Hjarup (SE); Laura Varas, Lund (SE); Mattias Levin, Lund (SE); Anna Säll, Lund (SE); and Laura von Schantz, Lund (SE)
Assigned to ALLIGATOR BIOSCIENCE AB, Lund (SE)
Filed by ALLIGATOR BIOSCIENCE AB, Lund (SE)
Filed on Nov. 13, 2023, as Appl. No. 18/507,736.
Application 18/507,736 is a continuation of application No. 17/980,751, filed on Nov. 4, 2022, granted, now 11,873,348.
Claims priority of application No. 2115925 (GB), filed on Nov. 5, 2021; application No. 2204539 (GB), filed on Mar. 30, 2022; and application No. 2212801 (GB), filed on Sep. 2, 2022.
Prior Publication US 2024/0117074 A1, Apr. 11, 2024
Int. Cl. C07K 16/00 (2006.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01)

CPC C07K 16/468 (2013.01) [A61P 35/00 (2018.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/77 (2013.01)]

14 Claims

1. A bispecific polypeptide comprising a first binding domain, designated B1, which is capable of binding specifically to CD40, and a second binding domain, designated B2, which is capable of specifically binding to carcinoembryonic antigen (CEA),

wherein the first and second binding domains are antibodies or antigen-binding fragments thereof;

wherein binding domain B1 comprises the three Complementarity Determining Regions (CDRs) of the heavy chain and the three CDRs of the light chain of antibody ffAC 05337 (SEQ ID NOs: 81, 82 and 83; and SEQ ID NO: 96, GNI, and SEQ ID NO: 98); and

wherein binding domain B2 comprises the three CDRs of the heavy chain and the three CDRs of the light chain of antibody ffAC 05337 (SEQ ID NOs: 216, 217, and 239; and SEQ ID NO: 90, AAS, and SEQ ID NO: 311).